文献速递白血病

妊娠期诊断的慢性髓性白血病:欧洲白血病网国际登记处报告的87例患者管理与结局

Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry.
PubMed 文献 · Leukemia · 2024-02-23

该研究基于欧洲白血病网(ELN)支持的最大国际观察性登记处,报告了2001-2022年间诊断的87例慢性期妊娠期慢性髓性白血病(CML)患者的治疗与结局。76%的患者正常分娩,未增加出生异常或危及生命事件的发生率,低出生体重率为12%,与正常人群相当。选择性流产和自然流产分别占21%和3%,分娩前完全血液学缓解率在伊马替尼组为95%,仅干扰素组为47%,妊娠期间未观察到疾病进展,28%的患者在产后不同时间更换治疗。

要点

  • 妊娠期CML患者中76%正常分娩,未增加出生异常或危及生命事件。
  • 低出生体重率12%,与正常人群相当。
  • 分娩前完全血液学缓解率:伊马替尼组95%,仅干扰素组47%。

核心结论

  • 妊娠期CML的治疗选择需平衡母婴疗效与安全性:干扰素-α可在妊娠早期开始,并在疾病控制良好且耐受性好的情况下持续整个孕期;因胎盘透过有限,选择性酪氨酸激酶抑制剂(伊马替尼和尼洛替尼)在妊娠中晚期似乎是安全有效的选择,而羟基脲获益甚少。

研究设计与样本

  • 基于欧洲白血病网(ELN)支持的最大国际观察性登记处,纳入299例CML女性的400次妊娠,其中2001-2022年间诊断的87例慢性期妊娠期CML患者。

主要发现

  • 正常分娩发生于76%的患者,未增加出生异常或危及生命事件的发生率,包括未治疗或妊娠中晚期接受干扰素-α和/或伊马替尼治疗的患者。
  • 低出生体重率为12%,与正常人群所见相当。
  • 选择性流产和自然流产分别发生于21%和3%的患者。
  • 分娩前完全血液学缓解率:伊马替尼组为95%,仅干扰素组为47%。
  • 妊娠期间未观察到疾病进展;28%的患者在产后不同时间更换治疗。

临床怎么用

  • 干扰素-α可在妊娠早期开始,并在疾病控制良好且耐受性好的情况下持续整个孕期。
  • 因胎盘透过有限,选择性酪氨酸激酶抑制剂(伊马替尼和尼洛替尼)在妊娠中晚期似乎是安全有效的选择。
  • 羟基脲在妊娠期CML中获益甚少。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The management of chronic myeloid leukemia (CML) diagnosed during pregnancy is a rare and challenging situation. We report the treatment and outcome of 87 cases diagnosed in chronic phase from 2001-2022 derived from the largest international observational registry, supported by the European LeukemiaNet (ELN), of 400 pregnancies in 299 CML women. Normal childbirth occurred in 76% without an increased rate of birth abnormalities or life-threatening events, including in patients untreated or treated with interferon-α and/or imatinib in 2nd-3rd trimester. The low birth weight rate of 12% was comparable to that seen in the normal population. Elective and spontaneous abortions occurred in 21% and 3%, respectively. The complete hematologic response rate before labor was 95% with imatinib and 47% with interferon only. No disease progression during pregnancy was observed, 28% of the patients switched their therapy at varying times after delivery. Treatment options balance the efficacy and safety for mother and infant: interferon-α can commence in the 1st trimester and continued throughout in cases of good disease control and tolerability. Because of limited placental crossing, selected tyrosine kinase inhibitors (imatinib and nilotinib) seem to be safe and effective options in 2nd and 3rd trimester while hydroxycarbamide offers few benefits.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Chelysheva E, Apperley J, Turkina A, et al. Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry. Leukemia. 2024. PMID: 38388649. doi:10.1038/s41375-024-02183-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。